Dr. Reddy's Laboratories Ltd. (RDY)

NYSE: RDY · IEX Real-Time Price · USD
51.15
0.47 (0.93%)
May 17, 2022 3:48 PM EDT - Market open
Market Cap8.49B
Revenue (ttm)2.58B
Net Income (ttm)234.85M
Shares Out165.96M
EPS (ttm)2.04
PE Ratio25.02
Forward PE19.57
Dividend$0.34 (0.67%)
Ex-Dividend Daten/a
Volume231,728
Open50.85
Previous Close50.68
Day's Range50.66 - 51.26
52-Week Range47.88 - 75.50
Beta0.15
AnalystsBuy
Price Target67.78 (+32.5%)
Earnings DateMay 13, 2022

About RDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics bu...

IndustryPharmaceuticals
Founded1984
CEOG. Prasad
Employees22,739
Stock ExchangeNYSE
Ticker SymbolRDY
Full Company Profile

Financial Performance

In 2020, RDY's revenue was 189.72 billion, an increase of 8.66% compared to the previous year's 174.60 billion. Earnings were 17.24 billion, a decrease of -11.59%.

Financial numbers in millions INRFinancial Statements

Analyst Forecast

According to 45 analysts, the average rating for RDY stock is "Buy." The 12-month stock price forecast is 67.78, which is an increase of 32.51% from the latest price.

Price Target
$67.78
(32.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

New Strong Sell Stocks for May 12th

CHUY, RDY, and FBC have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2022.

Other symbols:CHUYFBC
5 days ago - Zacks Investment Research

11 Emerging Market Stocks That Analysts Love

Right now, it's easy to be down on the global stock market. While the U.S. market is off about 7% so far in 2022, emerging market stocks are about 10% lower than where they were to start the year.

3 weeks ago - Kiplinger

Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- #DRREDDY--Dr. Reddy's Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market.

3 weeks ago - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. M...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- #DRREDDY--Dr. Reddy's Laboratories announces the launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market.

1 month ago - Business Wire

Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany

AUGSBURG, Germany & VANCOUVER, British Columbia & HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories and MediCane Health announce the launch of medical cannabis products in Germany.

1 month ago - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- #DrReddys--Dr. Reddy's Laboratories announces the launch of its authorized generic version of VASOSTRICT® Vials in the U.S. Market.

3 months ago - Business Wire

NYSE-Listed Pharma Co. Dr. Reddy's To Acquire German Medical Cannabis Firm Nimbus Health GmbH

Pharmaceutical company Dr. Reddy's Laboratories Ltd. RDY has entered into a definitive agreement to acquire Nimbus Health GmbH, a medical cannabis-focused licensed pharmaceutical wholesaler from Germany.

3 months ago - Benzinga

Dr. Reddy's Laboratories Enters Into Definitive Agreement to Acquire German Medical Cannabis Firm Nimbus Health GmbH

FRANKFURT, Germany & HYDERABAD, India--(BUSINESS WIRE)-- #DrReddys--Dr. Reddy's Laboratories enters into definitive agreement to acquire German medical cannabis firm Nimbus Health GmbH.

3 months ago - Business Wire

Dr. Reddy's Included in S&P Global's Sustainability Yearbook for the 2nd Year and Bloomberg Gender-Equality Index for...

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy's”) announces two major back-to-back recogni...

3 months ago - Business Wire

Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year

Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.

3 months ago - Zacks Investment Research

Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters

India-based Dr Reddy's Laboratories Ltd (NYSE: RDY) will launch its generic version of Merck Co & Inc's (NYSE: MRK) COVID-19 antiviral pill, reported Reuters. A company spokesperson said Reddy's would l...

Other symbols:MRK
4 months ago - Benzinga

3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure

The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.

Other symbols:AMPHTEVA
4 months ago - Zacks Investment Research

Dr. Reddy's and Prestige BioPharma announce partnership to commercialize biosimilar for cancer treatment in select co...

HYDERABAD, India--(BUSINESS WIRE)-- #DRREDDY--Prestige BioPharma and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy's”) today ...

5 months ago - Business Wire

Prestige BioPharma and Dr. Reddy's Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries i...

SINGAPORE & HYDERABAD, India--(BUSINESS WIRE)-- #DRREDDY--Prestige BioPharma and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Redd...

5 months ago - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...

5 months ago - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...

5 months ago - Business Wire

New Strong Sell Stocks for November 22nd

RDY, FRO, WWW, PGR, and LGIH have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2021.

Other symbols:FROLGIHPGRWWW
5 months ago - Zacks Investment Research

Dr. Reddy's Ready To Make COVID-19 Antiviral From Pfizer - Reuters

Dr. Reddy's Laboratories Ltd (NYSE: RDY) said it was open to making Pfizer Inc's (NYSE: PFE) COVID-19 antiviral pill, Reuters reported. The new drugs can be used to treat patients once they contract cor...

Other symbols:PFE
6 months ago - Benzinga

New Strong Sell Stocks for November 4th

ALX, RDY, HSC, LAWS, and ANDE have been added to the Zacks Rank #5 (Strong Sell) List on November 4, 2021.

Other symbols:ALXANDEHSC
6 months ago - Zacks Investment Research

Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.

6 months ago - Zacks Investment Research

Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...

6 months ago - Business Wire

Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...

6 months ago - Business Wire

Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy...

7 months ago - Business Wire

AiPharma Signs Binding Agreement To Sell To Aditxt Inc (Nasdaq: ADTX). AiPharma Is The Rights Holder Of Antiviral Tab...

DUBAI, United Arab Emirates, Oct. 5, 2021 /PRNewswire/ -- AiPharma Global Holdings LLC ("AiPharma") a company focused on discovering, developing and commercializing antiviral therapies across a broad sp...

Other symbols:ADTX
7 months ago - PRNewsWire

Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy

Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.

8 months ago - Zacks Investment Research